Tulmimetostat

N/A

Report date: 2026/05/07 20:00:36
NME

Base Information

Drug NameTulmimetostat
Drug Alias NameCPI-0209DZR123DZR-123
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone-lysine N-methyltransferase EZH2 inhibitorsHistone-lysine N-methyltransferase EZH1 inhibitors
TargetsHistone-lysine N-methyltransferase EZH2Histone-lysine N-methyltransferase EZH1
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsSolid tumoursProstatic Neoplasms, Castration-Resistant +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesSingapore +[16] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesConstellation Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesCatalent Greenville IncWashington University School Of MedicineNovartis Pharma Ag +[4] 
Inactive CompaniesN/A
Active IndicationsHormone-Sensitive Prostate NeoplasmsSolid tumoursProstatic Neoplasms, Castration-Resistant +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A